Literature DB >> 11020247

Development of daptomycin for gram-positive infections.

F P Tally1, M F DeBruin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11020247     DOI： 10.1093/jac/46.4.523

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  62 in total

1.  The Advantage of Bactericidal Drugs in the Treatment of Infection.

Authors:  Jeffrey Alder; Barry Eisenstein
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

2.  Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations.

Authors:  Peter A Smith; Tucker C Roberts; Floyd E Romesberg
Journal:  Chem Biol       Date:  2010-11-24

3.  Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors.

Authors:  Christopher M Bland; P Brandon Bookstaver; Z Kevin Lu; Brianne L Dunn; Kathey Fulton Rumley
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

Review 4.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

5.  Structure-activity studies of divin: an inhibitor of bacterial cell division.

Authors:  Maoquan Zhou; Ye-Jin Eun; Ilia A Guzei; Douglas B Weibel
Journal:  ACS Med Chem Lett       Date:  2013-09-12       Impact factor: 4.345

6.  Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children.

Authors:  Kanokporn Mongkolrattanothai; Robert S Daum
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

7.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.

Authors:  Kenneth H Rand; Herbert J Houck
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae.

Authors:  M I Restrepo; J A Velez; M L McElmeel; C G Whitney; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 10.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.